Overview of Randomized Trials of Systemic Adjuvant Therapy

  • Peter M. Ravdin
Part of the Cancer Treatment and Research book series (CTAR, volume 103)


The most influential analyses of the effectiveness of systemic adjuvant therapy of breast cancer are the 3 overview meta-analyses performed at Oxford and published in 19881, 19922, and 19983. These meta-analyses are a collaborative effort dependent on pooling of data by trialists of nearly all the randomized clinical trials of systemic adjuvant therapies. The major questions that were addressed by these Overview analyses were:
  1. 1)

    Is systemic adjuvant therapy of breast cancer effective?

  2. 2)

    Are there subsets of patients in whom given adjuvant therapies are particularly effective?

  3. 3)

    How effective is the current adjuvant therapy?



Estrogen Receptor Endometrial Cancer Menopausal Status Node Positive Patient Adjuvant Tamoxifen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Anonymous. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28,896 women. Early Breast Cancer Trialists’ Collaborative Group. N Engl J Med 319: 1681–1692, 1988.CrossRefGoogle Scholar
  2. 2.
    Anonymous. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Early Breast Cancer Trialists’ Collaborative Group. Lancet 339:1–15, 71–85, 1992.Google Scholar
  3. 3.
    Anonymous. Tamoxifen for early breast cancer: an overview of randomised. Early Breast Cancer Trialists’ Collaborative Group. Lancet 351: 1451–1467, 1998.CrossRefGoogle Scholar
  4. 4.
    Ravdin PM. How can prognostic and predictive factors in breast cancer be used in a practical way today?. Recent Results in Cancer Research. 152: 8693, 1998.CrossRefGoogle Scholar
  5. 5.
    Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88: 1543–1549, 1996.CrossRefGoogle Scholar
  6. 6.
    Fisher B, Dignam J, Bryant J, deCillis A, Wickerham DL, Wolmark N, et al. The worth of five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88: 1529–1542, 1996.PubMedCrossRefGoogle Scholar
  7. 7.
    Anonymous. Ovarian ablation in early breast cancer: An overview of randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 348: 1189–1196, 1996.CrossRefGoogle Scholar
  8. 8.
    Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, Bowman D, Couture J, Dimitrov NV, Evans J, Farrar W, Kavanah M, Lickley HL, Margolese R, Paterson AHG, Robidoux A, Shibata H, Terz J. Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B14. J Natl Cancer Inst 86: 527–537, 1994.PubMedCrossRefGoogle Scholar
  9. 9.
    Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115: 860–864, 1991.PubMedGoogle Scholar
  10. 10.
    Henderson IC, Berry D, Demetri G. et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc Am. Soc. Clinical Oncology 17: 390a, 1998.Google Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Peter M. Ravdin
    • 1
  1. 1.University of Texas Health Science Center at San AntonioUSA

Personalised recommendations